Abstract Introduction: Several preclinical studies provided relevant evidences that lysine oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. To investigate the clinical significance of LOXL2, we performed survival analysis with LOXL-2 in breast cancer patients. Method: A cohort treated at Gangnam Severance hospital, Seoul, Korea between January 1996 and December 2004 was studied. The immunohistochemical analyses with LOXL-2 antibody were performed in the 309 patients. The patients was stratified into two groups based on the expression level of LOXL-2. Kaplan-Meier and Cox's methods were used to define prognostic factors associated with breast cancer survival. Results: LOXL-2 positive group was 50 patients (16.2%) and 259 patients (83.8%) are LOXL-2 negative group. The proportion of estrogen receptor-negative patients was significantly higher in LOXL-2 positive group (54.0 vs. 37.0 %, P = 0.040). The Kaplan-Meier overall survival estimate at 5 year for the breast cancer patients with negative LOXL-2 was higher than that for the patients with positive LOXL-2 (88.0 vs. 71.8 %, P = 0.008). In the multivariate analysis for overall survival, lymph node metastasis (Hazard Ratio (HR) 0.32, 95% confidence interval (CI) 0.17–0.61) and positive LOXL-2 (HR 0.53, 95% CI 0.29–0.97) were significantly associated. In the multivariate analysis for distant metastasis-free survival, age younger than 35 years (HR 0.52, 95% CI 0.30–0.91), lymph node metastasis (HR 0.29, 95% CI 0.16–0.54), high histologic grade (HR 0.54, 95% CI 0.32–0.89) and positive LOXL-2 (HR 0.55, 95% CI 0.31–0.97) were demonstrated as significant prognostic factors. Conclusion: In breast cancer patients, overexpression of LOXL-2 is a poor prognostic factor for overall survival and distant metastasis-free survival. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-14.